Eternex-M 500 Tablet SR is a combination oral antidiabetic medication containing Metformin 500 mg and Teneligliptin 20 mg, designed to improve glycemic control in patients with type 2 diabetes mellitus. Metformin, a biguanide, works primarily by decreasing hepatic glucose production and enhancing insulin sensitivity in peripheral tissues, thereby reducing blood glucose levels. Teneligliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, increases the levels of incretin hormones, which stimulate insulin secretion and suppress glucagon release in a glucose-dependent manner. The sustained-release formulation of Eternex-M 500 ensures a gradual release of Metformin, minimizing gastrointestinal side effects commonly associated with immediate-release forms and improving patient compliance. This combination therapy is particularly beneficial for patients inadequately controlled on Metformin alone or those requiring dual therapy to achieve target blood glucose levels. It is recommended to be taken as prescribed by a healthcare professional, typically once or twice daily with meals to reduce gastrointestinal discomfort. Patients should be monitored regularly for renal function and any adverse effects such as hypoglycemia, gastrointestinal disturbances, or allergic reactions. Eternex-M 500 Tablet SR offers an effective and convenient option for managing type 2 diabetes, helping to maintain long-term glycemic control and reduce the risk of diabetes-related complications.